As of the latest Form 4 filed Jun 4, 2026.
What Bio-Techne Corp insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 26 most recent filings for TECH.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | 2026-06-02 | Crouse Steven C. President - Diag & Spatial Bi | FTax | −216.00 | $49.77 | $10.8K | No | Form 4 ↗ |
| 2026-06-04 | 2026-06-02 | Crouse Steven C., President - Diag & Spatial Bi | MExercise | +600.00 | — | — | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-08 | Herr Amy E. Director | SSale | −6.64K | $48.28 | $320K | No | Form 4 ↗ |
| 2026-05-12 | 2026-05-08 | Herr Amy E., Director | MExercise | +6.64K | $47.60 | $316K | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Hippel James CFO | FTax | −57.0K | $56.68 | $3.23M | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Hippel James, CFO | MExercise | +62.0K | $47.60 | $2.95M | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Bohnen Shane SVP - General Counsel | FTax | −7.05K | $56.68 | $400K | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Bohnen Shane, SVP - General Counsel | MExercise | +8.40K | $47.60 | $400K | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Kelderman Kim Chief Executive Officer | FTax | −24.0K | $56.68 | $1.36M | No | Form 4 ↗ |
| 2026-05-07 | 2026-05-05 | Kelderman Kim, Chief Executive Officer | MExercise | +26.7K | $47.60 | $1.27M | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Crouse Steven C. President - Diag & Spatial Bi | FTax | −311.00 | $55.02 | $17.1K | No | Form 4 ↗ |
| 2026-05-05 | 2026-05-01 | Crouse Steven C., President - Diag & Spatial Bi | MExercise | +794.00 | — | — | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Kelderman Kim Chief Executive Officer | FTax | −1.36K | $58.58 | $79.8K | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Kelderman Kim, Chief Executive Officer | MExercise | +11.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Hippel James CFO | FTax | −56.1K | $58.58 | $3.29M | No | Form 4 ↗ |
| 2026-04-24 | 2026-04-22 | Hippel James, CFO | MExercise | +62.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Kelderman Kim Chief Executive Officer | FTax | −32.1K | $58.66 | $1.88M | No | Form 4 ↗ |
| 2026-04-16 | 2026-04-14 | Kelderman Kim, Chief Executive Officer | MExercise | +36.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-03 | Bohnen Shane SVP - General Counsel | FTax | −740.00 | $53.13 | $39.3K | No | Form 4 ↗ |
| 2026-04-07 | 2026-04-03 | Bohnen Shane, SVP - General Counsel | MExercise | +2.26K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-19 | 2026-02-17 | Herr Amy E. Director | SSale | −1.98K | $59.11 | $117K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Herr Amy E. Director | FTax | −16.00 | $64.63 | $1.03K | No | Form 4 ↗ |
| 2026-02-05 | 2026-02-03 | Herr Amy E., Director | MExercise | +38.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-03 | 2026-02-01 | McManus Matthew President - Diag & Spatial Bio | FTax | −1.67K | $64.09 | $107K | No | Form 4 ↗ |
| 2026-02-03 | 2026-02-01 | McManus Matthew, President - Diag & Spatial Bio | MExercise | +4.62K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | Klimovsky Judith V Director | AAward | +680.00 | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TECH’s full analysis or the market-wide insider trading feed. The tabs above jump to TECH’s other SEC data.
Source: SEC Form 4 filings for TECH, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.